NRADD (neurotrophin receptor alike death domain protein) is a novel protein with transmembrane and cytoplasmic regions highly homologous to death receptors, particularly p75 NTR . However, the short N-terminal domain is unique. Expression of NRADD induced apoptosis in a number of cell lines. The apoptotic mechanism involved the activation of caspase-8 and execution of apoptosis without requiring mitochondrial components. The activation of this death receptor-like mechanism required the N-terminal domain, which is Nglycosylated and needed for subcellular targeting. Deletion of the N-terminal domain produced a dominant-negative form of NRADD that protected neurons and Schwann cells from a variety of endoplasmic reticulum (ER) stressors. NRADD may therefore be a necessary component for generating an ERinduced proapoptotic signal.
Introduction
Since the discovery of the homology between the death promoting Caenorhabditis elegans gene Ced3 and the interleukin-1b-converting enzyme (caspase-1), numerous mammalian gene products involved in apoptosis have been identified based via homology. 1 Prevalent among these are proteins containing domains belonging to the death domain (DD) superfamily. This superfamily is defined by its conserved tertiary structure and consists of the DD, the caspase recruitment domain (CARD), and the death effector domain (DED) families of proteins. 2 The function of these domains is to mediate homotypic interactions between specific members of each family. The pyrin domain, for which a structure has not been solved yet, functions in a similar manner and has been proposed to belong to the DD superfamily as well. 3 Death receptors are transmembrane proteins belonging to the TNFR/NGFR superfamily that contain a DD in their cytoplasmic tail. 4 They are activated by the binding of their cognate ligands to the extracellular domain. Activation of death receptors can induce apoptosis as in the case of Fas or the pleiotropic responses observed with TNFR1. The mechanism by which apoptosis is induced by death receptors is surprisingly direct. The adaptor molecule FADD is sufficient to transmit the signal from death receptors to the apical caspase-8 and 10. In some cell types cleavage of BID by caspase-8 is required to enhance the signal via mitochondrial components. JNK and NF-kB pathways are nonapoptotic signaling cascades activated by death receptors. Proximally, these pathways use the same receptor signaling molecules, as do apoptotic pathways, but different adaptor molecules are engaged distally.
The p75 NTR death receptor is particularly complex because it physically and functionally interacts with the Trk neurotrophin receptors. Therefore, its proapoptotic activity is often masked or even reversed. In addition, p75
NTR binds with lowaffinity neurotrophins, which do not belong to the TNF ligand family. 5 Recently, proneurotrophins have been identified as the high-affinity proapoptotic ligands for p75 NTR . 6 Apoptotic signaling from p75 NTR has several steps in common with signaling from other death receptors, but the receptor proximal adaptor molecules are different. 7 Intriguingly, despite extensive efforts no homotypic interaction partner for the p75 NTR DD has been identified. A plethora of molecules mediating p75 NTR signal transduction have been identified mainly on the basis of protein-protein interactions. 5 Their precise involvement in the multiple signals that emanate from p75 NTR remains to be elucidated. Death receptors permit the cell to receive proapoptotic signals from the extracellular milieu. However, apoptosis is also a frequent cellular response to insults that affect intracellular components. For example, apoptosis induced by stressors of the endoplasmic reticulum (ER) is thought to involve activation of ER-membrane components by luminal proteins. 8 Ire1 and PERK are ER-associated kinases containing conserved luminal domains. ER chaperones, specifically GRP proteins like BiP/GRP78, are thought to bind these domains and keep them in an inactive state. 9 Induction of BiP/ GRP78 is a protective response and confers resistance to ER stressors. The same kinases also induce the activation of the JNK pathway using similar adaptor molecules as the death receptors. 10 Whether JNK activation by ER stressors is pro-or antiapoptotic is not fully understood. Activation of caspase-12 is the best understood molecular event of the proapoptotic signals emanating from the ER. 11 Calpain, Traf2, and caspase-7 have all been proposed to activate caspase-12. [12] [13] [14] It is unclear how these upstream mediators communicate with ER components and whether they are each activated by a subset of ER death stimuli or if they act in concert. The Ire kinases induce apoptosis at least in part by inducing the transcriptional factor CHOP. 15 As CHOP À/À mice show only a modest reduction in cell death, additional proapoptotic pathways are probable.
Here we describe the molecular cloning and characterization of a new molecule with homology to the intracellular domain of p75 NTR . This type III transmembrane protein, termed neurotrophin receptor alike death domain protein (NRADD), is widely expressed during development and in adult tissues. NRADD expression induces apoptosis using an apoptotic pathway similar to the one used by death receptors.
The N-terminal domain has an N-glycosylation consensus site and is necessary for the induction of apoptosis. A dominantnegative form of NRADD inhibits apoptosis induced by several stressors of the ER. This inhibition is observed in immortalized neurons as well as Schwann cells, suggesting that NRADD may mediate ER stress-induced apoptosis.
Results
EST databases were searched for DD superfamily proteins to identify new molecules potentially involved in apoptosis. Using the DD of p75 NTR as the search query, a new DDcontaining protein was discovered and the full-length (FL) sequence was obtained from an embryonic mouse library. An in-frame upstream stop codon confirmed that the sequence was indeed FL. The stop codon was also present in several other mammalian sequences assembled from ESTs ( Figure 1a ). The human cDNA was assembled from the contig The putative intracellular domain  consists of two more exons with similar boundaries to those of  p75 NTR , suggesting that the two genes were derived from the same progenitor by exon shuffling. The mammalian sequences show a high degree of conservation except for the 18 N-terminal amino acids encoded by the first exon. However, an N-glycosylation consensus site remains conserved at Asn4.
This new protein has extensive homology not only to the DD of p75 NTR (54%), but also to the juxtamembrane domain (55%) and the transmembrane domain (88%) of p75 NTR . Based on these sequence comparisons the molecule was named NRADD. However, the short N-terminal domain of NRADD lacks any homology to the extracellular domain of p75 NTR or any other TNFR/NGFR superfamily member. The signal peptide sequence found in all other death receptors is not present in NRADD. Analysis of the DD sequence of NRADD revealed that all the amino acids constituting the hydrophobic core are conserved, which suggests a secondary structure consisting of the same six a-helices as found in the other DDs (not shown). The NRADD's DD is most similar to that of p75 NTR with 44% identity and shares about 20% of the amino acids with other death receptors. The DD of FAS and TNFR1 are the least related with B13% identity.
NRADD is widely expressed during development and in adult tissues
Northern blot analysis of RNA isolated during different stages of development and adult tissues revealed NRADD mRNA of two sizes (B2.4 and B1.4 kb, Figure 1b ). Both forms are expressed throughout development. In most adult tissues expression is weaker and only the lower band is discernible (Figure 1c ). Both RNA sizes are detected in lung and testis where expression is high. NRADD expression was also assayed qualitatively by RT-PCR in all cell lines used in this study. Only the embryonic kidney epithelial cell line 293 was negative for NRADD expression (not shown). A similar, but not identical, broad expression pattern is also observed for p75 NTR . For example, ST14A cells used in this study do not express p75
NTR , but do express NRADD.
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NRADD induces apoptosis in a subset of cells DD containing molecules are frequently involved in transmitting apoptotic signals and expression of these proteins will trigger cell death. To ascertain whether NRADD has proapoptotic activity, constructs expressing FL-NRADD were transiently transfected into a panel of cell lines and the propidium iodide (PI) staining pattern of the transfected cells was evaluated 48 h later (Figure 2a ). In the parental striatal cell line, ST14A, about 15% of NRADD transfected cells were scored as apoptotic, which is significantly higher than in cells transfected with the GFP control (5%). The extent of killing increased with the amount of transfected NRADD (inset). NRADD was also assayed in ST14A cells stably transfected with a ponasterone-inducible p75 NTR construct to investigate a potential synergy between these homologous proteins. 7 NRADD-induced cell death in this line was similar to that observed in the parental line. Combining the p75 NTR apoptotic stimulus, by adding ponasterone, with NRADD transfection produced B40% killing in the transfected cells. Although this is clearly higher than with either stimulus alone, the effect is only additive and not synergistic.
Expression of NRADD also induced cell death in neuroblastoma lines SHEP and SHSY5Y. Furthermore, primary Schwann cells isolated from rat embryos were the most susceptible to NRADD killing. No significant cell death was observed in PC12, 293, and MCF7 cells. NIH3T3 and HeLa cells were also resistant to NRADD killing (not shown). These results indicate that NRADD is moderately proapoptotic in several cell types, but not in other cells that have been shown to be susceptible to death receptor killing.
ST14A lines stably transfected with NRADD were generated to study NRADD-induced cell death in more detail. FLAG-tagged NRADD was expressed under the control of ecdysone promoter, so that expression of the protein is induced by the addition of ponasterone. The level of protein expression was measured by Western blotting (Figure 2b ). Three classes of clones were obtained: (i) clones represented by 4 and 9, which show no expression in the absence of ponasterone and good inducibility, (ii) clones with poor induction and NRADD expression in the absence of ponasterone (clone 8), and (iii) clones with no expression even after induction (clone 5). The extent of cell death was measured by comparing the viability of ponasterone-treated cells with the untreated controls (Figure 2c ). Ponasterone killed more than 70% of the cells during a 48 h exposure in the clones with inducible NRADD expression. No change in viability was seen in the nonexpressing clone 5, which was similar to the vector control. NRADD stable lines were also generated in MCF7 and NIH3T3 cells. Induction of NRADD was not cytotoxic in these cells, confirming the cell-type specificity observed in the transient transfection assays (not shown). NRADD mRNA levels were measured in stably transfected and parental ST14A cells to determine whether the strong proapoptotic activity observed in the inducible stable lines was because of gross overexpression. Northern blot analysis revealed only about a two-fold increase of NRADD in the stable transfectants (Figure 2d ), suggesting comparable levels of exogenous and endogenous NRADD.
The cells killed by ponasterone displayed the apoptotic morphology of shrunken rounded cells with membrane blebs (not shown). To ascertain at a molecular level that cell death proceeded by an apoptotic mechanism, DNA from NRADDexpressing cells was compared to the noninduced control ( Figure 2e ). NRADD expression induced a DNA ladder pattern of B200 bp periodicity characteristic of cells undergoing apoptosis.
NRADD signals apoptosis similar to death receptors
Caspase activity was measured in lysates from cells undergoing NRADD-induced apoptosis (Figure 3a ). Caspasespecific substrates were used in order to distinguish between different subgroups. Significant caspase-3-like (DEVD) activ-ity was induced consistent with the induction of the apoptotic effector machinery. Of the apical caspases tested in this assay, only caspase-8-like activity (IETD) increased significantly. Caspase-1-like activity (YVAD) did not increase at all and only an insignificant increase in caspase-9-like activity (LEHD) was detected. This caspase activation pattern is reminiscent of death receptor signaling in cells, which do not require a mitochondrial amplification loop. Furthermore, addition of BAF, a broad-range caspase inhibitor, inhibited NRADD-induced cell death. NRADD therefore requires caspase activation to induce apoptosis. We also assayed the activation status of caspase-12, another apical caspase, by Western blot analysis. Induction of NRADD by ponasterone resulted in the cleavage of caspase-12, a common indicator of its activation (Figure 3b ). 11 The same cleavage products were also induced by treatment with the ER stressor brefeldin A. Caspase-12 was not processed in this cell line by the DNA damaging agent etoposide. A NRADD-specific response is also indicated by the lack of caspase-12 processing by ponasterone treatment in the vector control line (not shown). Thus, NRADD expression leads also to activation of caspase-12, a caspase implicated in ERmediated apoptosis.
To further map which apoptotic pathways are activated by NRADD, apoptotic inhibitors with specific targets were employed ( Figure 3c ). Cell death was induced in ST14A by transfection with FL-NRADD. Upon cotransfection of the various inhibitors, differing degrees of protection were observed. The vFLIP proteins E8 and MC159 decreased the amount of apoptosis to background levels. The caspase inhibitors CrmA and p35 also conferred significant protection. In contrast, Bcl-x L , a potent inhibitor of multiple death pathways that involve release of proapoptogenic factors from mitochondria, did not have any effect. Similarly, caspase-9 dominant negative, an inhibitor of apoptosome activation, was also inactive. Bcl-x L and caspase-9 DN were functional in ST14A cells as evidenced by their ability to inhibit the p75 NTR proapoptotic signal. 7 This inhibitor profile suggests that NRADD induces apoptosis by a mechanism that does not require factors released from the mitochondria nor the subsequent effector complex, the apoptosome.
Induction of apoptosis by NRADD requires the N-terminal domain
Deletion mutants were tested to identify which domains of NRADD are necessary for generating a proapoptotic signal ( Figure 4A, B) . Expression of the FL-NRADD constructs induced apoptosis within 48 h in 20-25% of SHEP cells and in more than 30% of Schwann cells. Deletion of the ecto-domain (ECD) completely inactivated NRADD. Furthermore, the putative intracellular domain (ICD) or the DD alone was similarly inactive. NRADD without a death domain (DDD) retains significant proapoptotic activity, particularly in Schwann cells. This mutational analysis indicated that the ECD is the strongest determinant of NRADD's apoptotic activity. The extracellular domain of p75 NTR was replaced with the ECD of NRADD to find out if this activity was autonomous and could elicit similar effects on other transmembrane proteins. Deletion of the extracellular domain of p75 NTR eliminated the proapoptotic activity as reported previously in cellular systems. 16 Fusion of the ECD of NRADD recovered half of the apoptotic activity observed with the wild type (wt)-p75 NTR . Therefore, the short ECD is required for the proapoptotic activity of NRADD and it can function in a heterologous context of other proapoptotic transmembrane proteins.
NRADD is a type III transmembrane protein
To monitor the intracellular distribution of NRADD, C-terminal GFP and N-terminal FLAG constructs were expressed in ST14A and 293 cells, respectively ( Figure 4C ). FL-NRADD autofluorescence was detectable in the perinuclear region 8 h after transfection (a). Cotransfection of an ER-targeted yellow fluorescent protein (ER-YFP) with the red-tagged NRADD (RFP) revealed a high degree of colocalization (c). On the other hand, mitotracker stain did not colocalize with NRADD (b), suggesting that NRADD is retained initially in the ER prior to transport to the cell membrane, typical for transmembrane proteins. After 24 h, NRADD-GFP fluorescence was distributed throughout the cell and accumulated nonuniformly at the cell surface and in cell extensions (d). Neither mitotracker nor ER marker colocalized significantly with NRADD 24 h, posttransfection. To further confirm that NRADD was expressed on the cell surface, 293 cells were transfected with N-terminal AU1-tagged NRADD (f). Subsequent FACS analysis was performed using a-AU1 antibodies without permeabilization. The specific AU1 signal indicates a surface exposed Nterminus and is consistent with NRADD being a type III transmembrane protein. This FACS analysis was also performed with FLAG-tagged NRADD yielding the same result (not shown). Penetration of the N-terminus through a lipid bilayer is also predicted by the positive-inside rule. 17 Six positively charged amino acids are located on the C-terminal side of the putative TM domain and none on the N-terminal side.
C-terminal GFP fusions of wt NRADD and deletion mutants were transfected into ST14A cells to further characterize the determinants for subcellular localization (g-o). Cellular membranes were stained with the lipophilic dye DiD (h, k, n) 24 h after transfection. Comparison of the FL-NRADD apparent (n,o) . This distribution was indistinguishable from GFP alone (not shown). While these results clearly reveal that the ECD and the putative TM domains are required for membrane localization, they also show that the putative ICD contributes to direct NRADD to the cell membrane.
NRADD is N-glycosylated
The predicted molecular weight of NRADD is 25 kDa. Expression of NRADD, however, yields a band of B37 kDa. The mouse amino-acid sequence contains the N-glycosylation consensus site (NXS/T) at N4 and N37 (Figure 1 ). The N4 site is conserved in all species, while N37 is not found in the bovine and pig sequences. These putative sites were mutated and the resulting constructs expressed in 293 cells to investigate whether NRADD is glycosylated ( Figure 5 ). Expressions were also performed in the presence of tunicamycin, an inhibitor of N-glycosylation. FL-NRADD yielded the largest molecular weight band while the single mutants were of intermediate size. All constructs had the same fastest mobility in the presence of tunicamycin. The double mutant N4Q/N37Q expressed poorly and only a weak band comigrating with tunicamycin-treated NRADD was detectable. Low expression of N4Q/N37Q is probably because of proteolysis as indicated by the accumulation of smaller bands.
To confirm the mutational analysis, FLAG-NRADD was expressed in 293 cells, purified by immunoprecipitation and deglycosylated in vitro by PNGase F (Figure 5b ). The same reduction in size was obtained by PNGase F treatment as by expression in the presence of tunicamycin. Inhibition of Nglycosylation had no effect on the DECD construct, indicating that the only sites N-glycosylated on NRADD are N4 and N37 on the ECD.
The localization of NRADD-GFP expressed in the presence of tunicamycin was determined (Figure 5c ). The nonglycosylated NRADD accumulated in the perinuclear regions, similar to the ER localization observed 8 h after transfection ( Figure  4c ). This retention in the ER is similar to that seen with other Nglycosylated proteins. 18 Deletion of the ECD also leads to retention in the ER (Figure 7b) . wt NRADD-myc was poorly expressed and addition of tunicamycin increased the expression of wt NRADD to the level of the point mutants (Figure 5a ). Treatment with tunicamycin does not normally lead to increased expression levels of transfected proteins. Moreover, glycosylated NRADD is susceptible to degradation as evidenced by the degradation products seen with NRADD tagged with myc at the C-terminus but not with the FLAG epitope placed on the Nterminus. Modification of the N-terminus by the FLAG tag also stabilizes NRADD (Figure 5b ). These observations suggest that modifications of the ECD by glycosylation or by epitope tags affect NRADD stability.
NRADD activates the JNK pathway
Transmembrane proteins with DDs often activate multiple signaling pathways in addition to caspases. Luciferase reporter assays were performed to address whether NRADD has also the potential to trigger multiple intracellular signals ( Figure 6 ). Transfection of NRADD induced a robust induction of an AP-1 reporter construct in a dose-dependent manner in ST14A cells (Figure 6a ). The maximum level of induction was comparable to MEKK1, a known inducer of this pathway. The AP-1 promoter is controlled not only by JNK activation but other signaling pathways as well. An ATF2-GAL4 fusion protein provided a more specific read-out. ATF2 is a substrate for the p38 kinase and the activity of a GAL4 promoter yields a measure of activation of the p38 pathway. Cotransfection of NRADD with the ATF2 reporter system produced a four-fold induction of luciferase in a dose-dependent manner ( Figure  6b ). CHOP (GADD153) is also a transcription factor that is a Figure 4C substrate for p38 and promotes cell death induced by ER stress. 15, 19 A GAL4-CHOP fusion protein was used to measure the induction of its transactivation activity by NRADD (Figure 6c) . A similar dose-response curve as with ATF2 was observed. This survey therefore indicates that NRADD has the potential to activate multiple kinase cascades possibly affecting other cellular functions in addition to apoptosis.
ER-mediated apoptosis is inhibited by NRADD dominant negative
To obtain insight into the physiological function of NRADD, deletion mutants were screened for a dominant negative effect on the proapoptotic activity of FL-NRADD. ST14A cells stably expressing FL-NRADD in the ecdysone system were transiently transfected with vector or the potential inhibitors (Figure 7a ). Expression of DECD eliminated almost all the proapoptotic activity of NRADD. The inhibition was similar to that observed with E8, the most effective inhibitor against transient expression of NRADD (Figure 7a, 3c) .
Since the DECD mutant lacks the N-terminal domain that is important for localization, we determined its subcellular localization by cotransfection with ER-targeted YFP and a DECD-RFP fusion protein. The red fluorescence accumulated in a perinuclear punctate pattern that colocalized with the ER marker suggesting that DECD NRADD is retained in the ER (Figure 7b) . Stable ST14A lines expressing DECD NRADD in the ecdysone system were established to identify an apoptotic phenotype in cells that expressed NRADD DN (Figure 7c ). The cells were subjected to several apoptotic insults in the presence and absence of ponasterone. Addition of ponasterone to these cells causes a moderate level of cytotoxicity compatible with the low level of toxicity observed with DECD NRADD in transient assays ( Figure 4B ). However, in combination with the ER stressors thapsigargin, tunicamycin, and brefeldin A, induction of DECD NRADD by ponasterone produced significant protection. Thapsigargin induces cell death by inhibiting the Ca 2+ -dependent ER ATPase. Tunicamycin is a potent inhibitor of N-glycosylation, and brefeldin A interferes with vesicle transport between the ER and Golgi. 20 The protection against ER stress was specific as treatment with TNF-a, etoposide, and UV produced more killing in the presence of ponasterone. In addition, the effect size was greater in clones with good induction than in pooled transfectants, which have a lesser degree of inducibility of the dominant negative.
To establish a protective effect in a primary cell of neural origin, Schwann cells were used because they express NRADD (not shown) and are also sensitive to NRADD killing (Figure 2a) . Schwann cell transfectants expressing DECD NRADD constitutively were selected and subjected to the same treatments as above (Figure 7c ). Vector controls were isolated and assayed in parallel. The protection pattern was similar to that observed in ST14A cells. The cytotoxicity of thapsigargin was completely eliminated for the 24 h duration of the experiment. A high degree of specificity is indicated by the lack of protection against TNF-a and etoposide. Furthermore, Schwann cells were not protected from apoptosis induced by serum withdrawal.
The protective activity of NRADD DN suggests that FL-NRADD induces cell death through the ER. The localization of NRADD DN to the ER and FL-NRADD to the cell membrane indicates that the inhibition is not mediated by direct interaction. These experiments do not reveal whether ER stressors activate NRADD directly and do not pinpoint the signaling event that is susceptible to NRADD DN. They imply, however, that additional proteins, such as NRADD, are involved in the already complex response of the ER to stress in higher eucaryotes.
Discussion
The NRADD protein is a hybrid between a sequence with high homology to the intracellular domain of p75 NTR and a short unique N-terminal domain. The cysteine-rich domains that define the TNFR/NGFR superfamily are not part of NRADD. 4 Therefore, NRADD represents a new class of membrane proteins with a DD. NRADD is a type III transmembrane protein, as it lacks a leader sequence and its N-terminus has the potential to protrude through cellular membranes. Whereas most TNFR/NGFR superfamily members are type I transmembrane proteins, a few such as TACI and XEDAR are targeted to membranes without a leader sequence.
The sequence described here contains 52 additional Nterminal amino acids compared to GeneBank BAB25059, which was identified from a genomic approach to clon FL sequences. 21 In our longer sequence, the initiator methionine is preceded by an in-frame stop codon and is part of a Kozak consensus sequence. Assembly of ESTs from other vertebrates revealed initiator methionines with the same properties, suggesting that the FL sequence was obtained. In addition, the analysis of ESTs and mRNA revealed multiple isoforms (not shown, and Figure 1 ). These shorter forms were not investigated here.
Transient expression of NRADD was moderately cytotoxic in a limited number of cell types. NRADD cytotoxicity was drastically enhanced in stable transfectants. NRADD induces cell death by an apoptotic mechanism as indicated by the DNA degradation pattern and activation of caspases. Significant differences exist between the apoptotic mechanisms of NRADD and its homologue p75 NTR . Apoptosis induced by p75 NTR was also analyzed in the ST14A system facilitating a comparison. 7 NRADD induces a caspase-8-like activity, while the only apical caspase induced by p75 NTR is caspase-9. Bclx L and caspase-9 DN, which are potent inhibitors of p75 NTR in multiple systems including ST14A cells, 7 do not affect apoptosis induced by NRADD. These results are consistent with an NRADD-induced apoptotic pathway that does not require any mitochondrial components. Such a direct pathway of activating caspases has previously only been described for death receptors in type I cells. 22 NRADD also triggers other signaling pathways such as the activation of AP-1 promoter or p38 kinase. Some of these pathways potentially contribute to the apoptotic activity of NRADD, especially p38, which has been shown to phosphorylate and activate CHOP, a transcription factor that is induced by ER stress. 19 Mutational analysis indicated that the intracellular signaling of NRADD is different from p75
NTR . The DD of p75 NTR is required to induce apoptosis in ST14A cells. 7 However, deletion of the DD in NRADD leads to a molecule that retains some of its proapoptotic potential in transient assays. This implies that the membrane proximal sequence is able to activate caspases. The homologous domain of p75 NTR has been named chopper domain and induces apoptosis in sensory neurons. 23 Interestingly, the chopper domain is particularly effective in the absence of the extracellular domain of p75 NTR , a construct that closely resembles NRADD except for the signal sequence. Cys 279 of p75 NTR , identified as a necessary residue for chopper activity, is not found in NRADD but it is possible that the nearby Cys76 of NRADD functions analogously. A number of proteins have been reported to interact with the chopper domain of p75 NTR . 24 The signaling pathways activated by these p75 NTR interacting proteins are not yet fully elucidated, and some of the same proteins could also be involved in transducing signals from the highly homologous juxtamembrane domain of NRADD.
We have assayed for homotypic interaction with other DDcontaining proteins and found that other death receptors (p75 NTR , TNFR1, FAS, DR3, 4, 5, 6), and adaptor molecules (FADD, TRADD, RAIDD) did not coimmunoprecipitate with NRADD (data not shown). The lack of homotypic interaction partners is also a property of the DD of p75 NTR , suggesting The N-terminal domain is important for proapoptotic activity as its deletion causes loss of function and dominant interference with the killing of FL-NRADD. By analogy to other receptors, binding of a ligand to this domain would be the most likely mechanism. Since the short ECD has no homology to an established ligand-binding domain, likely ligands cannot be proposed. However, the mutational analysis is consistent with a ligand binding to the ECD. Furthermore, glycosylation of the ECD is required for maturation of NRADD in the ER. Death receptors are also glycosylated on their extracellular domains, but the functional significance is poorly understood. In contrast to NRADD, studies with p75 NTR have shown that N-glycosylation is not required for cell surface expression. 25 Deletion of the ECD caused NRADD to be retained in the ER, consistent with its role in cellular targeting. Ligand binding and subcellular targeting are not mutually exclusive and the ECD could provide both functionalities. A further indication that the ECD is required but not sufficient to induce apoptosis is the inability of the ECD/TM-GFP construct to kill ST14A cells (not shown). Moreover, levels of NRADD protein were increased by placing a FLAG tag at the N-terminus or by treatment with tunicamycin. Together with the N-terminal proteolytic degradation products observed this may indicate that the ECD also affects protein stability.
Most significantly, NRADD DN retained in the ER interferes with apoptotic stimuli generated by ER stress. A well-understood physiological stimulus of ER stress is the unfolded protein response (UPR). The signaling pathways of the UPR in yeast are well understood, however, in higher eucaryotes the UPR is more sophisticated and is able to respond to a wide variety of stress signals with more diverse downstream effects including induction of apoptosis. The luminal ligand(s) that trigger the ER response have not been fully identified. Several kinases with a domain protruding into the ER lumen have been shown to be involved in protective responses. 8 ERmediated apoptosis triggers a cascade that leads to the activation of caspase-12.
11,26 Calpain, caspase-7, and TRAF2 have all been proposed to be part of this cascade. [12] [13] [14] Given the diversity of inducers of ER stress, different cascades may be activated depending on the insult. In ST14A cells, NRADD expression did result in caspase-12 processing. However, further studies are needed to establish whether NRADD interacts with the known components of the ER-mediated cell death pathway or if it functions through other effector pathways. Initial experiments did not reveal any binding of caspase-12 to NRADD in coimmunoprecipitation assays (not shown). Supporting an alternative, caspase-12 independent pathway, is the observation that NRADD activates caspase-8 and is susceptible to vFLIP inhibition. Such a pathway could involve Bap31, an ER protein that has been shown to associate with caspase-8 and is involved in transmitting apoptotic signals. 27 The ER stress response is not only activated by pharmacological agents, but has also been implicated in several disease states in which mutated proteins are retained in the ER. 28 For example, the b-amyloid precursor protein (APP) is processed in the ER to yield the two peptides Ab42 and Ab40. The ER apoptotic pathway is implicated by the observation that cortical neurons from caspase-12 À/À mice are protected from Ab induced cytotoxicity. 11 Some reports have suggested that the UPR response is deficient in cells expressing diseasecausing presenilin mutants. 29 These observations have been challenged and novel mechanisms that are distinct from the classical UPR pathway have been postulated. 30 However, it is unclear how the proapoptotic signal is generated. A molecule like NRADD could generate this signal particularly if it is activatable by amyloid peptides. Further investigations of the interplay between the multiple ER responses and NRADD are needed to uncover the potential role of NRADD in pathological responses to cellular stress.
Materials and Methods

Reagents and antibodies
Zeocin and ponasterone were from Invitrogen (Carlsbad, CA, USA), Hygromycin B from Roche (Indianapolis, IN, USA). Lipofectin and lipofectamine 2000 were from GIBCO BRL (Gathersburg, MD, USA). MTS kit was from Promega (Madison, WI, USA). Caspase substrates were from Stratagene (La Jolla, CA, USA). DNAzol was from Molecular Research Center, Inc. (Cincinnati, OH, USA). PNGase F reagents were from Prozyme (San Leandro, CA, USA). DNA sequencing and oligonucleotide synthesis services were from the University of Michigan core facilities. PI, poly-L-lysine hydro bromide, and a-FLAG M2 antibody were from Sigma (St Louis, MO, USA). a-GFP, pGFP, and pDsRed2 vectors were from Clontech Laboratories, Inc (Palo Alto, CA, USA). DiD stain was from Molecular Probes (Eugene, OR, USA). a-Myc antibodies were from BABCO (Richmond, CA, USA). Secondary antibodies and ECL reagents were from Amersham Life Science (Piscataway, NJ, USA).
Cell lines
ST14A, a conditionally immortalized cell line from the rat striatum, 31 SHEP and SH-SY5Y, human neuroblastoma cell lines, PC12 cells, a rat pheochromocytoma line, and 293 cells, a human embryonic kidney cell line, were cultured in Dulbecco's modified Eagle's medium (DMEM) medium supplemented with 10% fetal bovine serum (FBS) 0.1 mM nonessential amino acids, 2 mM L-glutamine, and penicillin/streptomycin in 5% CO 2 at 371C. ST14A cells were cultured at 331C. The serum for PC12 cells was heat inactivated and supplemented with 5% horse serum. MCF7 cells, a human breast carcinoma cell line, and HeLa cells, a human cervical carcinoma cell line, were cultured in RPMI 1640 medium supplemented as above. A-431 carcinoma cells were grown in DMEM/F 12 (1 : 1) supplemented as above plus 0.25 mg/ml amphotericin B. Schwann cells were isolated from sciatic nerve of neonatal rats as described previously. 32 Briefly, a single-cell suspension was obtained by trypsin and collagenase digestion followed by culturing in 10% FBS, 6 mM L-glutamine, 100 U/ml penicillin/100 mg/ml streptomycin, 20 mg/ml pituitary extract, and 2 mM Forskolin on poly-L-lysine-coated tissue culture dishes at 371C.
Expression vectors
Epitope-tagged expression constructs were made in pcDNA3.1-myc-His-A (À) and pcDNA3.1/zeo vectors ( Figure 4A ). The GFP and RFP fusion proteins were constructed in pEGFP and pDsRed2 vectors, respectively. For inducible expression, the coding region was subcloned into the ecdysone-inducible mammalian expression vector pIND-Hygro (Invitro-gen). A human p75 NTR plasmid (hp75) was kindly provided by Moses V Chao (New York University). All constructs were verified by sequencing and expression in 293 cells. AP-1, Gal4-ATF2, Gal4-CHOP plasmids were from Stratagene (La Jolla, CA, USA). 
Transfections
Library screening
The mouse embryo day 14.5 Lambda cDNA library in the Uni-ZAP XR vector system was purchased from Stratagene. The library was screened using the EST AV149215 according to standard protocols. 33 
Northern blot
Commercially available mouse multiple tissue Northern blots were probed by FL-mNRADD according to the manufacturer's instructions (Clontech, Palo Alto, CA, USA). The blots were also hybridized with a b-actin cDNA probe. For the cell line Northern blot, total RNA was isolated from ST14A cells using the Trizol reagent (GIBCO), then mRNA was prepared using the Oligotex kit (Qiagen). mRNA (3 mg) was loaded on each lane. The blot was hybridized with a ratNRADD cDNA probe and b-actin.
MTS assay
About 5 Â 10 4 cells were seeded per well in 96-well plate with 100 ml medium, then cells were either treated with ponasterone or left untreated. Combined MTS/PMS (20 ml) solution was added to each well, incubated at 371C for 1 h, and absorbance was read at 490 nm.
DNA fragmentation assay
About 5 Â 10 6 FL-NRADD ST14A transfectants treated with ponasterone or left untreated were harvested by DNAzol. The DNA was purified by EtOH precipitation. The precipitate was dissolved in H 2 O, digested 30 min at 371C with 20 mg/ml of DNAse-free RNAse, then analyzed by agarose electrophoresis.
Microscopic determination of cell death
Cells were grown on gelatin-coated coverslips and cotransfected with GFP as a marker (0.25 mg) and NRADD expression constructs (1 mg). For experiments with inducible stable transfectants, cells were transfected similarly but, in addition, treated with ponasterone or left untreated after transfection. Cells were washed with PBS and fixed with 4% paraformaldehyde, incubated for 10 min in 0.5 mg/ml PI, and washed with PBS. Transfected (green) cells were scored by fluorescence microscopy for a PI staining pattern indicating chromatin condensation and nuclear fragmentation.
Fluorescence microscopy
ST14A transfectants were cultured on gelatin-coated coverslips. For DiD staining, cells were washed in Optimem media stained with 5 ml/ml DiD in Optimem for 8 min. Cells were washed three times with Optimem for 30 min, the last wash containing DAPI (10 mg/ml). Fixation was in 4% fresh formaldehyde in media at RT for 10 min followed by two washes in PBS. Confocal microscopy was performed using a Zeiss LSM 510.
FACS analysis
293 cells were transiently transfected with AU1-FL-FLAG construct. After 24 h, a single cell suspension was prepared, washed in PBS, blocked with 10% goat serum 5% BSA in PBS for 30 min, and incubated with a-AU1-antibody (1 : 100) for 10 min. Incubation with FITC-conjugated secondary antibody (1 : 2000) was for 1 h. All processing was performed at 41C. The cells were analyzed on a Beckman Flow Cytometer.
Caspase activity assays
Cell extracts and enzyme assays were performed as previously described. 7 The following tetrapeptide substrates were used: caspase-1-like, Ac-YVAD-AFC; caspase-3-like, Ac-DEVD-AFC; caspase-8-like, Ac-IETD-AFC; caspase-9-like, Ac-LEHD-MCA. Caspase-12 processing was assayed in whole-cell lysates using the a-caspase-12 antibody from Junying Yuan (Harvard Medical School, Boston, MA, USA) as described.
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In vitro deglycosylation FLAG-NRADD was purified form transfected 293 cell by FLAG immunoprecipitation . The beads were resuspended in 135 ml of PNGase buffer and 7.5 ml of denaturation buffer, heated for 5 min at 1001C, cooled to RT and 7.5 ml Triton X-100 was added. The suspension was split equally and 50 U of PNGase F was added to one aliquot. Incubation was overnight at 371C followed by SDS-PAGE.
Luciferase assay
Luciferase assay was performed following the manufacturer's instruction (Dual luciferase kit, Promega, Madison, WI, USA) using the renilla plasmid pRC-Tk to normalize for transfection efficiency.
Apoptosis induction
DECD-NRADD-transfectants (ST14A or Schwann cells) were exposed to one of the following treatments: 0.3 mM thapsigargin, 5 mg/ml tunicamycin, 2 mg/ml brefeldin A, 100 ng/ml TNF-a plus 10 mM cycloheximide, 0.1 mM etoposide for 24 h. Where indicated, ST14A cells were treated with 1 mM ponasterone during this time period. ST14A transfectants were irradiated with a germicidal UV light (254 nm, 15 J). Following irradiation, the transfectants were supplied with media with or without 1 mM ponasterone for 48 h. For serum deprivation, Schwann cells were cultured in 1% BSA for 24 h.
Statistical analysis
StatView software was used to calculate significant differences by ANOVA. P-values o0.05 were considered significant and are indicated (*). Error bars indicate standard errors (S.E.).
